Peregrine`s 2C3 Antibody Therapy Inhibits Pancreatic Tumor Growth
by 50% in Pre-Clinical Studies (Note: Mentions a brain tumor trial)
Posted on: 05/18/2004
Peregrine's 2C3 Antibody Therapy Inhibits Pancreatic Tumor Growth
by 50% in Pre-Clinical Studies
TUSTIN, Calif., May 18 /PRNewswire-FirstCall/ -- Peregrine
Pharmaceuticals, Inc. (Nasdaq: PPHM) announced today that Dr. Rolf Brekken, a
scientific advisor to Peregrine, presented an overview and current status of
Peregrine's 2C3 anti-angiogenesis antibody program at the Third Annual
Angiogenesis Conference in London, England. The review, titled "Selective
Inhibition Of VEGFR2 Activity With a Monoclonal Anti-VEGF Antibody," gave a
historical overview of past research and an outlook for future research
programs for the 2C3 technology. Peregrine's 2C3 antibody works by inhibiting
a key tumor blood vessel growth factor known as Vascular Endothelial Growth
Factor (VEGF) from inducing the formation of blood vessels in solid tumors.
The 2C3 antibody is part of Peregrine's anti-angiogenesis compound family
under development for the treatment of cancer and other diseases dependent on
aberrant blood vessel formation.
Previously published pre-clinical data presented at the meeting
demonstrated that 2C3 could be effective in treating cancer. VEGF-dependent
angiogenesis is a key factor in pancreatic tumor growth, metastasis and
cancer-related death. One of the studies presented evaluated the effect of
2C3 on the growth of heterotopic (subcutaneous) and orthotopic (tumor in the
pancreas) human pancreatic adenocarcinomas in mice. The study utilized
magnetic resonance, ultrasound and in vivo fluorescence imaging techniques to
evaluate the extent of tumor burden in mice bearing orthotopic pancreatic
tumors. Consistent with its anti-angiogenic activity, 2C3 decreased total
microvessel density, immature microvessel density, VEGFR2 levels, and vascular
perfusion in responsive tumors. 2C3 also controlled the growth of human
pancreatic tumor cells injected in the pancreas such that the 2C3 treated mice
had primary tumors 50% smaller than tumors in mice that received a control
treatment. In addition, 2C3 therapy reduced the number and size of metastatic
colonies in the liver as well as the number of mice with metastatic disease.
No therapy-related toxicity was observed in any of these studies.
VEGF is a potent growth factor that plays a role in a number of normal
processes including blood vessel formation (angiogenesis) and immune system
regulation. The 2C3 antibody selectively blocks VEGF binding to one of its
two key receptors, VEGF receptor 2, without blocking binding to VEGF receptor
1. VEGF binding to VEGF receptor 2 is believed to be the primary signal
involved in new blood vessel formation, including tumor angiogenesis. VEGF
binding to VEGF receptor 1 is believed to be involved in other normal
VEGF-mediated processes. Anti-angiogenesis agents that selectively block the
blood vessel growth function of VEGF without blocking other VEGF-mediated
functions may have safety advantages over VEGF inhibition strategies that
block all VEGF functions. Additional information regarding Peregrine's 2C3,
anti-angiogenesis programs and other useful information can be found on
Peregrine's recently released website at http://www.peregrineinc.com .
About Peregrine Pharmaceuticals, Inc.
Peregrine's research and development efforts focus on discovering and
developing products that affect blood flow to tumors. Peregrine's vascular
research programs fall under several different proprietary platforms including
Anti-Phospholipid Therapy (APT), Vascular Targeting Agents (VTAs), anti-
Angiogenesis and Vasopermeation Enhancement Agents (VEAs). The company has
research collaborations with pharmaceutical and biotechnology companies to
develop its VTA platform for therapeutic and diagnostic applications and
expects to enter its first APT compound into clinical trials for cancer
therapy during calendar year 2004.
Peregrine's vascular agents may also have applications in other
angiogenesis-dependent diseases besides cancer such as diabetes, arthritis,
skin disorders and eye diseases. Peregrine currently has exclusive rights to
over 190 U.S. and foreign patents and patent applications that broadly cover
its vascular programs. In addition, the company is currently evaluating its
proprietary technology for use in treating non-angiogenesis dependent diseases
such as viral infections. The company believes that the pre-clinical data
generated by the company and the broad nature of its intellectual property may
provide many opportunities for product development, partnering and licensing.
Peregrine's most clinically advanced therapeutic program is based on a
targeting platform outside vascular biology. This technology platform is
known as Tumor Necrosis Therapy (TNT) and targets dead or dying tumor cells
that are common to the majority of different tumor types. Cotara(TM), the
most clinically advanced TNT program, is currently in a Phase I clinical trial
for the treatment of colorectal carcinoma at Stanford University Medical
Center. In addition, we have received protocol approval from the U.S. Food
and Drug Administration ("FDA") to initiate a registration clinical study for
the treatment of brain cancer. The company is currently seeking a development
or funding partner to move the brain cancer program forward. The company
believes that continuing the clinical development of Cotara(TM) in tumor types
other than brain cancer will add significant value to the program. The
company has a research collaboration to develop immunocytokines based on the
TNT platform and a TNT-based agent has been developed and approved for the
treatment of lung cancer in China under a licensing agreement.
The company also operates a cGMP contract manufacturing facility for
monoclonal antibodies and recombinant proteins through its wholly owned
subsidiary Avid Bioservices, Inc. (http://www.avidbio.com). Avid produces clinical
trial materials to support Phase I through Phase III clinical trials for
biotechnology companies including Peregrine. Copies of Peregrine press
releases, SEC filings, current price quotes and other valuable information for
investors may be found on the website http://www.peregrineinc.com .
Safe Harbor Statement: This release may contain certain forward-looking
statements that are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Actual events or results may differ
from the company's expectations as a result of risk factors discussed in
Peregrine's reports on file with the U.S. Securities and Exchange Commission,
including, but not limited to, Peregrine's report on Form 10-Q for the quarter
ended January 31, 2004 and on Form 10-K for the year ended April 30, 2003.
Peregrine Investor Relations
Frank Hawkins and Julie Marshall
Hawk Associates, Inc.
(800) 987-8256 or
SOURCE Peregrine Pharmaceuticals, Inc.
Web Site: http://www.peregrineinc.com
Click HERE to return to brain tumor news headlines